Patents Assigned to Amunix Pharmaceuticals, Inc.
  • Chimeric polypeptide assembly and methods of making and using the same
    Patent number: 11713358
    Abstract: The present invention relates to bispecific chimeric polypeptide assembly compositions comprising bulking moieties linked to binding domains by cleavable release segments that, when cleaved are capable of concurrently binding effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable chimeric polypeptide assembly compositions.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: August 1, 2023
    Assignee: AMUNIX PHARMACEUTICALS, INC.
    Inventors: Volker Schellenberger, Fan Yang, Desiree Thayer, Bee-Cheng Sim, Chia-Wei Wang
  • Extended recombinant polypeptides and compositions comprising same
    Patent number: 10961287
    Abstract: The present invention relates to compositions comprising biologically active proteins linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of glucose-related diseases, metabolic diseases, coagulation disorders, and growth hormone-related disorders and conditions.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: March 30, 2021
    Assignee: Amunix Pharmaceuticals, Inc
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. Stemmer, Nathan Geething, Wayne To, Jeffrey L. Cleland
  • XTEN conjugate compositions and methods of making same
    Patent number: 10953073
    Abstract: The present invention relates to extended recombinant polypeptide (XTEN) compositions, conjugate compositions comprising XTEN and XTEN linked to cross-linkers useful for conjugation to pharmacologically active payloads, methods of making highly purified XTEN, methods of making XTEN-linker and XTEN-payload conjugates, and methods of using the XTEN-cross-linker and XTEN-payload compositions.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: March 23, 2021
    Assignee: Amunix Pharmaceuticals, Inc.
    Inventors: Volker Schellenberger, Vladimir Podust, Chia-Wei Wang, Bryant McLaughlin, Bee-Cheng Sim, Sheng Ding, Chen Gu
  • Binding fusion proteins, binding fusion protein-drug conjugates, XTEN-drug conjugates and methods of making and using same
    Patent number: 10870874
    Abstract: The present invention relates to binding fusion protein compositions comprising targeting moieties linked to extended recombinant polypeptide (XTEN), binding fusion protein-drug conjugate compositions, and XTEN-drug conjugate compositions, isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of using such compositions in treatment of diseases, disorders, and conditions.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: December 22, 2020
    Assignee: Amunix Pharmaceuticals, Inc.
    Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Benjamin Spink, Willem P. C. Stemmer, Nathan C. Geething